Aguareles, JoséCarralón González, María MaravillasMartí Ballesteros, Eva MaríaPradillo Fernández, VirginiaSotres Fernández, GabrielGarcía de Viedma LaPetra, RocíoSánchez Manzano, María DoloresGutiérrez, CarolinaCarnevali Ruiz, Daniel Barrena Puertas, RuthLuque Pinilla, José ManuelGuisado Vasco, PabloEt al.2023-11-032023-11-032023Aguareles, J., Fernández, P. V., Carralón-González, M. M., Izquierdo, C. F., Martí-Ballesteros, E. M., Fernández, V. P., Sotres-Fernández, G., García-Delangue, T., García de Viedma LaPetra, R., Sánchez-Manzano, M. D., Gutiérrez, C., García-Coca, M., Carnevali-Ruiz, D., Barrena-Puertas, R., Luque-Pinilla, J. M., Lloris, R., Luepke-Estefan, X. E., López-Martín, J. A., Jimeno, J. M., & Guisado-Vasco, P. (2023). Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19. International Journal of Infectious Diseases, 135, 12–17. https://doi.org/10.1016/j.ijid.2023.07.0111201-97121878-3511http://hdl.handle.net/11268/12339Objectives: To evaluate the compassionate use of plitidepsin as an antiviral treatment in hospitalized immunocompromised adult patients with moderate-to-severe COVID-19 Design: Retrospective observational study of data -collected from January 01, 2021 to April 30, 2022- from 35 immunocompromised adult patients with COVID-19 non-eligible for other available antiviral treatments. Main outcome measures were time to respiratory recovery (SpFi ≥ 315); COVID-19-related 30-day-cumulative mortality after first plitidepsin infusion; and time to undetectable levels of viral RNA. Results: Thirty-three patients receiving a full course of plitidepsin (2.5 mg [n = 29] or 1.5 mg [n = 4]) were included. Most (69.7%) had a malignant hematologic disease and 27.3% had solid tumors. A total of 111 infusions were administered with lack of relevant safety events. Median time from plitidepsin initiation to SpFi ≥315 was 8 days (95% confidence interval [CI], 7-19). Median time to first negative reverse transcription-polymerase chain reaction for SARS-CoV-2 (cycle threshold >36) was 17 days (95% CI 13-25). Mortality rate was 16.3% (95% CI 3-37.3). Conclusion: These data support plitidepsin as a well-tolerated treatment that might have potential clinical and antiviral efficacy in COVID-19 immunocompromised patients. Keywords: COVID-19; Immunocompromised patients; Persistent viral SARS-CoV-2 replication; Plitidepsin; SARS-CoV-2.engAttribution-NonCommercial-NoDerivs 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19Huésped inmunocomprometidoTratamiento farmacológico de COVID-19journal article10.1016/j.ijid.2023.07.011open accessEnfermedad transmisibleTratamiento médicoMedicamento